Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Compound monograph · §10

GHK-Cu — references and citing documents

The full reference list for this monograph, and every Institute document that draws on it.

Document identifier
CEI-MN-033/10
Series
Compound monograph
Version
3.0
Published
08 Jan 2026
Last reviewed
08 Jan 2026
Next review
08 Jan 2028
Identifier
10.71829/cei.mono.33
Certainty
Low
Cycle
2026 Q1

§10References

Every reference the monograph relies on is listed below in order of first citation across the document. Identifiers are reproduced only where the Institute holds them; where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed one.

This monograph cites 4 sources[1,2,3,4].

Table 9. Bibliographic records for the sources cited by this monograph. Each links to its record page, which lists every Institute document citing it.

#TitleSourceYear
1Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene dataInternational Journal of Molecular Sciences2018
2Related impurities in peptide medicinesJournal of Pharmaceutical and Biomedical Analysis2014
3General Chapter ⟨788⟩ Particulate Matter in InjectionsUnited States Pharmacopeia — National Formulary (USP–NF)2024
4Stability of protein pharmaceuticals: an updatePharmaceutical Research2010

§11Related Institute documents

Table 10. Institute documents that draw on, or are drawn on by, this monograph.

Numbered reference list

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences 2018;19(7):1987. doi:10.3390/ijms19071987 · PMID 29986520
  2. D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
  3. United States Pharmacopeial Convention. General Chapter ⟨788⟩ Particulate Matter in Injections. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
  4. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6 · PMID 20143256

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.